Geson Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.80 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.14 Cr
- Satisfied Charges ₹ 7.77 M
- Revenue Growth -1.25%
- Profit Growth 66.64%
- Ebitda 5.39%
- Net Worth 9.87%
- Total Assets 10.12%
About Geson Pharma
Geson Pharma Private Limited (GPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 12 July 2010 and has a history of 14 years and seven months. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.80 M.
The company currently has active open charges totaling ₹1.14 Cr. The company has closed loans amounting to ₹7.77 M, as per Ministry of Corporate Affairs (MCA) records.
Shailendra Raghu and Prem Raghu serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24100UP2010PTC041332
-
Company No.
041332
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Jul 2010
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Geson Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailendra Raghu
|
Managing Director | 12-Jul-2010 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Prem Raghu
|
Director | 12-Jul-2010 | Current |
Financial Performance of Geson Pharma.
Geson Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.25% decrease. The company also saw a substantial improvement in profitability, with a 66.64% increase in profit. The company's net worth moved up by a moderate rise of 9.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Geson Pharma?
In 2023, Geson Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹11.45 M
₹7.77 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 1.14 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Oct 2021 | Hdfc Bank Limited | ₹1.14 Cr | Open |
| 22 Feb 2012 | Others | ₹7.77 M | Satisfied |
How Many Employees Work at Geson Pharma?
Unlock and access historical data on people associated with Geson Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geson Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geson Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.